Member Info for Fanti

Possibly GSK to blame. What if the Bod and CTA was badly mistaken in thinking GSK keep going on with SRA737, thus calculating with a milestone due early 2023 back in July. Could this this amount now be missing after GSK intends to revert the promising SRA737?

Was the last RNS about the likelihood that GSK hands it back since it says GSK intends to or may we expect an RNS instead stating facts saying GSK terminated its lease today.
What was the RNS then for, please?

SRA737 was licensed by CPF to Sierra in September 2016. Sierra progressed SRA737 through Phase 1/2 clinical development and, at the 2019 ASCO Annual meeting, reported positive preliminary efficacy and safety data from two clinical trials evaluating SRA737 as a monotherapy and in combination with chemotherapy. In addition, preclinical data have been reported that indicate triple drug combinations.

What to make of RNS minutes do not ackknowledge SO's patent registered in July 2022. Was it not worth mentioning or was the BOD not in the know?

Termination of contract could come into effect after a three or six or 12 month time of of notice, I would assume. Time enough to check and safehuard everything in detail.

Just wondering. Once we agree on 'Sierra retained that 'combo' patent', does this imply any revenue stream in future if ever used by the one or other Pharma company?
Thanks.

That’s well put and helpful information. BTW I was delighted about an RNS suggesting a milestone imminent that shall being paid 2/3 as an extraordinary dividend for a start and reward. Sweet dreams.

Now financially backed, SIERRA can well proceed with the research and participate from any collaboration GSK have in the pipe. Call it internal and external services they buy in.

GSK states re it’s Pipeline: ... For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified. Brand names are trademarks either owned by and/or licensed to GSK or associated companies.

I am not an expert in science at all but funny i find is GSK is invested in Curevac them with CV8102 in the pipe with results due in Q2. Curevac failed on the vaccine last year but seem to be experts in field of oncology also. Must not mean anything just funny to me anyway and mind boggling.
GLA

"toilet trade on shares". Thoth, your english and english in general ist just hilarious ::))
Loving
it.

I think there is no doubt about the strategy. Meaning comfortable dividends ahead at some stage.
What else to wish for?

Break even from today on. And hopefully forever. :)
GLA

No way shall there be a change. The BOD can be trusted while investors in the lead may manage to sell off bits and parts of the business for some strange and very own reason.

It’s up to Malrun to answer this question. I for one do not want to leave the party.

.. BIOME consolidated the odd shares were sold and I received the money. ..
My apologies asking a stupid question. Is it I am going to loose my shares? Who remains on board after consolidation then?
Thanks.

Fabulous sum. You are great.

Thanks Zylo. I didn‘t have a closer look into it. It was nice to learn about the terms at some stage, if appropriate. I might be right to say that any invention is on behalf of the employer, usually. We only can guess if a major player is involved now.

Maybe a stupid thought but I wonder if all inventors were already paid while on service or if the three next to Mr. Reader fancied an equal share on royalties when the on-license eventually comes to fruition.
Is there kind of a deal or are we done?

Much appreciated. Cheers, SOG.

My guess is the HNWI most likely wants to pay taxes on his advantage now rather when we sell @ 40GBP.

So in case Six Element Capital aka GP Ltd are not invested and therefore don‘t stress on any results , Tim could well have approached the parties.

Eieiei, sorry.
Administration, if any on CRT/CRF behalf.